t
On 7 April 2025, Diaceutics PLC issued a Block Listing Return for its UK and Global Share Incentive Plan (SIP) and Employee Share Option Plan (ESOP), which originally listed 1,500,000 Ordinary Shares on 6 October 2023. From 7 October 2024 to 6 April 2025, 71,443 Ordinary Shares were issued under these schemes. At the end of the period, 1,351,968 Ordinary Shares remained available under the schemes.
| Date | 7 Apr 2025 |
| Time | 10:33:24 |
| Category | Capital structure |
| ID | 9202D |
Diaceutics PLC
BLOCK LISTING RETURN
New York, Belfast and London, 7 April 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the UK and Global Share Incentive Plan for employees (the "SIP") and the Employee Share Option Plan (the "ESOP") which includes long-term incentive awards.
|
Name of applicant: |
Diaceutics PLC |
|||
|
Name of scheme: |
UK and Global Share Incentive Plan for employees (the "SIP") and the Employee Share Option Plan (the "ESOP") which includes long-term incentive awards. |
|||
|
Period of return: |
From: |
7 October 2024 |
To: |
6 April 2025 |
|
Balance under scheme from previous return: |
1,423,411 Ordinary Shares of £0.002 each |
|||
|
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: |
N/A |
|||
|
Number of securities issued/allotted under schemes during period: |
71,443 Ordinary Shares
|
|||
|
Balance under scheme not yet issued/allotted at end of period |
1,351,968 Ordinary Shares |
|||
|
Number and class of securities originally listed and the date of admission |
1,500,000 Ordinary Shares on 6 October 2023 |
|||
|
Total number of securities in issue at the end of the period |
84,798,378 Ordinary Shares of £0.002 each |
|||
|
Name of contact: |
Nick Roberts |
|||
|
Telephone number of contact: |
As below |
|||
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500
|
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.